ArrowMark Colorado Holdings’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-26,020
| Closed | -$2.5M | – | 358 |
|
|
2021
Q3 | $2.5M | Sell |
26,020
-571,579
| -96% | -$54M | 0.02% | 279 |
|
|
2021
Q2 | $58.2M | Sell |
597,599
-31,278
| -5% | -$3M | 0.44% | 71 |
|
|
2021
Q1 | $61.2M | Buy |
628,877
+29,573
| +5% | +$3.1M | 0.46% | 65 |
|
|
2020
Q4 | $57.4M | Buy |
599,304
+51,716
| +9% | +$5M | 0.45% | 70 |
|
|
2020
Q3 | $52.7M | Sell |
547,588
-7,152
| -1% | -$827K | 0.5% | 60 |
|
|
2020
Q2 | $67.7M | Buy |
554,740
+41,269
| +8% | +$4.56M | 0.7% | 49 |
|
|
2020
Q1 | $44.4M | Buy |
513,471
+25,019
| +5% | +$2.45M | 0.58% | 59 |
|
|
2019
Q4 | $52.5M | Buy |
488,452
+45,502
| +10% | +$4.76M | 0.47% | 68 |
|
|
2019
Q3 | $39.9M | Buy |
442,950
+54,140
| +14% | +$5.06M | 0.4% | 69 |
|
|
2019
Q2 | $32.8M | Sell |
388,810
-8,267
| -2% | -$679K | 0.32% | 87 |
|
|
2019
Q1 | $35M | Buy |
397,077
+18,382
| +5% | +$1.54M | 0.33% | 88 |
|
|
2018
Q4 | $27M | Buy |
378,695
+3,263
| +0.9% | +$313K | 0.28% | 100 |
|
|
2018
Q3 | $46.2M | Sell |
375,432
-341,012
| -48% | -$38.7M | 0.39% | 88 |
|
|
2018
Q2 | $70.4M | Sell |
716,444
-25,703
| -3% | -$2.3M | 0.65% | 60 |
|
|
2018
Q1 | $61.5M | Sell |
742,147
-55,567
| -7% | -$4.69M | 0.62% | 61 |
|
|
2017
Q4 | $61.9M | Sell |
797,714
-90,232
| -10% | -$6.15M | 0.63% | 59 |
|
|
2017
Q3 | $54.4M | Sell |
887,946
-7,633
| -0.9% | -$403K | 0.62% | 56 |
|
|
2017
Q2 | $41.2M | Sell |
895,579
-111,419
| -11% | -$5.4M | 0.51% | 71 |
|
|
2017
Q1 | $43.6M | Buy |
1,006,998
+115,471
| +13% | +$4.95M | 0.59% | 60 |
|
|
2016
Q4 | $34.5M | Buy |
891,527
+78,400
| +10% | +$3.55M | 0.55% | 60 |
|
|
2016
Q3 | $41.2M | Buy |
813,127
+51,667
| +7% | +$2.57M | 0.75% | 45 |
|
|
2016
Q2 | $34.6M | Buy |
761,460
+36,350
| +5% | +$1.67M | 0.7% | 48 |
|
|
2016
Q1 | $28.7M | Buy |
725,110
+235,002
| +48% | +$9.33M | 0.64% | 55 |
|
|
2015
Q4 | $27.7M | Sell |
490,108
-42,914
| -8% | -$2.18M | 0.76% | 42 |
|
|
2015
Q3 | $21.2M | Sell |
533,022
-189,827
| -26% | -$9.17M | 0.58% | 57 |
|
|
2015
Q2 | $34.5M | Sell |
722,849
-38,481
| -5% | -$1.63M | 0.84% | 41 |
|
|
2015
Q1 | $30.2M | Sell |
761,330
-712,159
| -48% | -$25.5M | 0.78% | 46 |
|
|
2014
Q4 | $32.9M | Sell |
1,473,489
-71,090
| -5% | -$1.35M | 0.85% | 36 |
|
|
2014
Q3 | $24.2M | Sell |
1,544,579
-112,094
| -7% | -$1.68M | 0.66% | 51 |
|
|
2014
Q2 | $24.6M | Buy |
1,656,673
+400,252
| +32% | +$5.65M | 0.7% | 51 |
|
|
2014
Q1 | $20.2M | Buy |
1,256,421
+658,580
| +110% | +$11.3M | 0.66% | 54 |
|
|
2013
Q4 | $5.58M | Buy |
597,841
+343,798
| +135% | +$3.35M | 0.17% | 144 |
|
|
2013
Q3 | $2.88M | Buy |
254,043
+6,476
| +3% | +$89K | 0.09% | 166 |
|
|
2013
Q2 | $3.31M | Buy |
+247,567
| New | +$3.04M | 0.89% | 32 |
|
Other funds holding NBIX
BG
EVM
ArrowMark Colorado Holdings's NBIX Position: Q4 2021 in Review
ArrowMark Colorado Holdings sold out of Neurocrine Biosciences (NBIX) in Q4 2021, closing a stake of 26,020 shares — an estimated $2.5M sold.
ArrowMark Colorado Holdings first reported a position in NBIX in Q2 2013 and held it in 34 quarters. The position peaked at $70.4M in Q2 2018. 405 funds tracked by Wall St. Rank hold NBIX as of Q4 2021.
- ArrowMark Colorado Holdings reported no remaining Neurocrine Biosciences position as of Q4 2021 after selling out during the quarter.
- ArrowMark Colorado Holdings sold 26,020 Neurocrine Biosciences shares in Q4 2021, an estimated $2.5M.
- ArrowMark Colorado Holdings first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 34 quarters.
- ArrowMark Colorado Holdings's Neurocrine Biosciences position peaked at $70.4M in Q2 2018.
- 405 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2021.
Based on ArrowMark Colorado Holdings's 13F filing for Q4 2021, filed 14 Feb 2022.